U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. PSG Database

Product-Specific Guidances for Generic Drug Development

To successfully develop and manufacture a generic drug product, an applicant should consider that their product is expected to be: pharmaceutically equivalent to its reference listed drug (RLD), i.e., to have the same active ingredient, dosage form, strength, and route of administration under the same conditions of use; bioequivalent to the RLD, i.e., to show no significant difference in the rate and extent of absorption of the active pharmaceutical ingredient; and, consequently, therapeutically equivalent, i.e., to be substitutable for the RLD with the expectation that the generic product will have the same safety and efficacy as its RLD.

According to 21 CFR 320.24, different types of evidence may be used to establish bioequivalence (BE) for pharmaceutically equivalent drug products, including in vivo or in vitro testing, or both. The selection of the method used to demonstrate BE depends upon the purpose of the study, the analytical methods available, and the nature of the drug product. Under this regulation, applicants must conduct BE testing using the most accurate, sensitive, and reproducible approach available among those set forth in 21 CFR 320.24. As the initial step for selecting methodology for generic drug product development, applicants are referred to the following draft guidance: Draft Guidance for Industry on Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application (ANDA) (August 2021).

To further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval, FDA publishes product-specific guidances (PSGs) describing the Agency's current thinking and expectations on how to develop generic drug products therapeutically equivalent to specific RLD.

FDA publishes these PSGs to foster drug product development, and ANDA submission and approval, ultimately providing increased access to safe, affordable generic drugs

These guidances are published in an incremental manner and listed below in alphabetical order according to the active ingredient's name. The most recently published guidances (new and revised) are listed below.

Additionally, as part of FDA's commitments under the Generic Drug User Fee Amendments Reauthorization of 20221 (GDUFA III). FDA will issue PSGs consistent with the following goals:

  • For complex products1,2 approved in new drug applications (NDAs) on or after October 1, 2022, a PSG will be issued for 50 percent of such NDA products within 2 years after the date of approval, and for 75 percent of such NDA products within 3 years after the date of approval.
  • FDA will continue to develop PSGs for complex products approved prior to October 1, 2022, for which no PSG has been published.
  • For non-complex drug products approved in NDAs on or after October 1, 2022, that contain a new chemical entity (NCE) (as described in section 505(j)(5)(F)(ii) of the FD&C Act), a PSG will be issued within 2 years after the date of approval for 90 percent of such products.
In addition to its GDUFA III commitments, FDA will prioritize publishing of PSGs based on public health priorities, drug availability and accessibility, public requests for guidance, stakeholder interest in ANDA submission.

In addition to the provided information, sponsors and investigators of any Investigational New Drug (IND)-exempt pharmacokinetic (PK) studies, pharmacodynamic (PD) studies, or BE and/or bioavailability (BA) studies involving human subjects in support of an ANDA should refer to the current RLD labeling, including BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections. This information should be considered during study design and conduct; including attention to appropriate subject screening and selection, inclusion and exclusion criteria, and appropriate clinical safety monitoring.

Some of the PSGs include discussion regarding data formats. Please note that under section 745A(a) of the Federal Food, Drug, and Cosmetic Act, separate Agency-wide guidances specify the electronic formats, subject matter, and scope of applicability for certain submissions, including submissions to ANDAs. As these are finalized guidances and subject to described timetables for implementation, these guidances are binding and the electronic format(s) specified must be used for submissions to ANDAs. Questions and general information regarding the preparation of submissions in electronic format may be directed to CDER at esub@fda.hhs.gov. Questions regarding submission of datasets to CDER may be sent to edata@fda.hhs.gov.

COMMENTS: The Agency is seeking feedback and considers comments to the docket on these guidances. You may submit comments on any guidance at any time as follows: Submit electronic comments to Docket FDA-2007-D-0369. For further information on submitting electronic comments, refer to (www.regulations.gov). You may also mail your written comments to DDM (HFA-305), FDA, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All submissions received must include the Docket No. [FDA-2007-D-0369]. Please contact the Regulations.gov Help Desk at 1-877-378-5457 (toll free) or at (www.regulations.gov/support) for assistance regarding submissions.

The FDA posts plans for issuing new or revised PSGs on the Upcoming Product-Specific Guidances for Generic Drug Product Development web page

For additional information on development of generic drug products, please refer to FDA's guidance document database.

1GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027 (GDUFA III Commitment Letter)

2Classifying Approved New Drug Products and Drug-device combination Products as Complex Products for Generic Drug Development Purposes (CDER MAPP 5240.10)

Total number of currently published PSGs: 2069

Product-Specific Guidances for Specific Products Arranged by Active Ingredient


Search by Active Ingredient or by RLD or RS Number


119 record(s) found for 'B'

Active Ingredient (link to Specific Guidance) URL Type Route Dosage Form RLD or RS Number Date Recommended
Bacitracin https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bacitracin_ophthalmic ointment_RLD61212_RV09-16.pdf Draft Ophthalmic Ointment 061212 10/01/2016
Baclofen https://www.accessdata.fda.gov/drugsatfda_docs/psg/Baclofen_tab_72235_72234_RC2-10.pdf Draft Oral Tablet 017851 02/01/2010
Baclofen https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021589.pdf Draft Oral Tablet, Orally Disintegrating 021589 11/01/2019
Baloxavir Marboxil https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210854.pdf Draft Oral Tablet 210854 09/01/2019
Balsalazide Disodium https://www.accessdata.fda.gov/drugsatfda_docs/psg/Balsalazide_cap_20610_RC1-08.pdf Draft Oral Capsule 020610 01/01/2008
Balsalazide Disodium https://www.accessdata.fda.gov/drugsatfda_docs/psg/Balsalazide_disodium_tab_022205_RC06-13.pdf Draft Oral Tablet 022205 06/01/2013
Baricitinib https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207924.pdf Draft Oral Tablet 207924 11/17/2022
Barium Sulfate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Barium sulfate_oral supension_NDA 208036_RC11-17.pdf Draft Oral Suspension 208036 02/01/2018
Barium Sulfate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Barium sulfate_oral supension_NDA 208143_RC11-17.pdf Draft Oral Suspension 208143 02/01/2018
Barium Sulfate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Barium sulfate_oral paste_NDA 208844_RC08-17.pdf Draft Oral Paste 208844 10/01/2017
Beclomethasone Dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020911.pdf Draft Inhalation Aerosol, Metered 020911 03/01/2020
Beclomethasone Dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Beclomethasone dipropionate Inhalation Aerosol Metered NDA 207921 PSG Page RC May 2019.pdf Draft Inhalation Aerosol, Metered 207921 05/01/2019
Beclomethasone Dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Beclomethasone dipropionate_draft_Nasal aerosol metered_RLD 202813_RC07-18.pdf Draft Nasal Aerosol, Metered 202813 07/01/2018
Beclomethasone Dipropionate Monohydrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019389.pdf Draft Nasal Spray, Metered 019389 11/08/2021
Bedaquiline Fumarate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bedaquiline_fumarate_tab_204384_RC11-13.pdf Draft Oral Tablet 204384 11/01/2013
Bempedoic Acid https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211616.pdf Draft Oral Tablet 211616 11/08/2021
Bempedoic Acid; Ezetimibe https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211617.pdf Draft Oral Tablet 211617 11/08/2021
Benazepril Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benazepril_HCl_tabs_19851_RC07-10.pdf Draft Oral Tablet 019851 07/01/2010
Benazepril Hydrochloride; Hydrochlorothiazide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benazepril HCL and hydrochlorothiazide_oral tablet_20033_RC09-15.pdf Draft Oral Tablet 020033 09/01/2015
Benoxinate hydrochloride; Fluorescein sodium https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benoxinate hydrochloride; Fluorescein sodium Ophthalmic solution drops 0.25-0.45 NDA 208582 PSG Page RC May 2019.pdf Draft Topical Solution/Drops 208582 05/01/2019
Benznidazole https://www.accessdata.fda.gov/drugsatfda_docs/psg/Beznidazole Oral Tablets NDA 209570 RC 09-2018.pdf Draft Oral Tablet 209570 09/01/2018
Benzonatate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benzonatate _oral capsule_040749 040627 201209_RV09-15.pdf Draft Oral Capsule 011210 09/01/2015
Benzoyl Peroxide; Clindamycin Phosphate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050819.pdf Draft Topical Gel 050819 11/01/2019
Benzoyl Peroxide; Clindamycin Phosphate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050741.pdf Draft Topical Gel 050741 11/01/2019
Benzoyl Peroxide; Clindamycin Phosphate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050756.pdf Draft Topical Gel 050756 11/01/2019
Benzoyl Peroxide; Erythromycin https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050557.pdf Draft Topical Gel 050557 11/01/2019
Benzoyl Peroxide; Erythromycin https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050769.pdf Draft Topical Gel 050769 11/01/2019
Benzphetamine Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Benzphetamine_HCl_tab_12427_RC5-06.pdf Final Oral Tablet 012427 05/01/2008
Benztropine Mesylate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_009193.pdf Draft Oral Tablet 009193 09/01/2019
Benzyl Alcohol https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022129.pdf Draft Topical Lotion 022129 10/21/2022
Berotralstat Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214094.pdf Draft Oral Capsule 214094 08/02/2022
Besifloxacin Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022308.pdf Draft Ophthalmic Suspension/Drops 022308 03/01/2020
Betamethasone Acetate; Betamethasone Sodium Phosphate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone_Acetate;_Sodium_Phosphate_Inj_14602_RC04-10.pdf Draft Injection Suspension, Injectable 014602 04/01/2010
Betamethasone dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_topical Lotion_NDA 01778_RC08-17.pdf Draft Topical Lotion 017781 10/01/2017
Betamethasone dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_topical augmented ointment_NDA 018741_RC11-17.pdf Draft Topical Ointment, Augmented 018741 02/01/2018
Betamethasone dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_draft_Topical spray_RLD 208079_RC07-18.pdf Draft Topical Spray 208079 07/01/2018
Betamethasone dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_ topical augmented cream_RLD 19555_RC04-16.pdf Draft Topical Cream, Augmented 019555 04/01/2016
Betamethasone dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone Dipropionate_topical cream 0.05_RLD 019137_RC09-16.pdf Draft Topical Cream 019137 10/01/2016
Betamethasone dipropionate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone dipropionate_topical augmented lotion_RLD 019716_RC01-16.pdf Draft Topical Lotion, Augmented 019716 01/01/2016
Betamethasone Dipropionate; Calcipotriene https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213422.pdf Draft Topical Cream 213422 10/21/2022
Betamethasone Dipropionate; Calcipotriene https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207589.pdf Draft Topical Aerosol, Foam 207589 11/01/2019
Betamethasone Dipropionate; Calcipotriene https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021852.pdf Draft Topical Ointment 021852 10/21/2022
Betamethasone Dipropionate; Calcipotriene https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022185.pdf Draft Topical Suspension 022185 10/21/2022
Betamethasone dipropionate;Clotrimazole https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone Dipropionate; Clotrimazole Lotion NDA 020010 RV Feb 2019.pdf Draft Topical Lotion 020010 02/01/2019
Betamethasone dipropionate;Clotrimazole https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone Dipropionate; Clotrimazole Cream NDA 018827 RV Feb 2019.pdf Draft Topical Cream 018827 02/01/2019
Betamethasone Valerate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone valerate_topical cream_RLD 018861_RC12-16.pdf Draft Topical Cream 018861 12/01/2016
Betamethasone Valerate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone_valerate_aerofoam_20934_RC12-14.pdf Draft Topical Aerosol, Foam 020934 12/01/2014
Betamethasone Valerate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone valerate_topical lotion_RLD 018866_RC01-16.pdf Draft Topical Lotion 018866 01/01/2016
Betamethasone Valerate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betamethasone valerate_topical ointment_RLD 18865_RC10-16.pdf Draft Topical Ointment 018865 10/01/2016
Betaxolol Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/BETAXOLOL HYDROCHLORIDE ophthalmic suspensiondrops NDA 019845 PSG Page RV May 2019.pdf Draft Ophthalmic Solution/Drops 019845 05/01/2019
Bethanechol Chloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bethanechol_Chloride_tab_88440_88441_89096_89095_RC9-08.pdf Draft Oral Tablet 006536 09/01/2008
Betrixaban https://www.accessdata.fda.gov/drugsatfda_docs/psg/Betrixaban_draft_Oral cap_RLD 208383_RC07-18.pdf Draft Oral Capsule 208383 07/01/2018
Bexarotene https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021055.pdf Draft Oral Capsule 021055 08/20/2021
Bexarotene https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021056.pdf Draft Topical Gel 021056 10/21/2022
Bicalutamide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bicalutamide_tab_20498_RC5-05.pdf Final Oral Tablet 020498 05/01/2008
Bictegravir Sodium; Emtricitabine; Tenofovir Alafenamide Fumarate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bictegravir Sodium, Emtricitabin, Tenofovir Alafenamide Fumarate Oral Tablet NDA 210251 page RC May 2019.pdf Draft Oral Tablet 210251 05/01/2019
Bimatoprost https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bimatoprost_ophthalmic solution drops_NDA 021275_RC11-17.pdf Draft Ophthalmic Solution/Drops 021275 02/01/2018
Bimatoprost https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bimatoprost_ophthalmic solution drops_NDA 022184_RC11-17.pdf Draft Ophthalmic Solution/Drops 022184 02/01/2018
Bimatoprost https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bimatoprost_ophthalmic solution drops_NDA 022369_RC11-17.pdf Draft Topical Solution/Drops 022369 02/01/2018
Binimetinib https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210498.pdf Draft Oral Tablet 210498 03/01/2020
Bisacodyl; Polyethylene Glycol 3350; Potassium Chloride; Sodium Bicarbonate; Sodium Chloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bisacodyl; PEG3350_ANDA 202217_RC03-17.pdf Draft Oral For Solution, Tablet, Delayed Release 021551 05/01/2017
Bismuth Subcitrate Potassium; Metronidazole;Tetracycline Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/BismuthSubcitratePotassiumMetronidazoleTetracyclineHClcap50786RC908.pdf Draft Oral Capsule 050786 09/01/2008
Bisoprolol Fumarate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bisoprolol_Fumarate_tab_19982_RC7-05..pdf Final Oral Tablet 019982 05/01/2008
Bisoprolol Fumarate; Hydrochlorothiazide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bisoprolol_Fumarate_HCTZ_tab_20186_RC7-05.pdf Final Oral Tablet 020186 05/01/2008
Boceprevir https://www.accessdata.fda.gov/drugsatfda_docs/psg/Boceprevir_Cap_202258_RC06-12.pdf Draft Oral Capsule 202258 06/01/2012
Bortezomib https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021602.pdf Draft Intravenous, Subcutaneous Injectable 021602 08/01/2020
Bosentan https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bosentan_tabs_21290_RC09-10.pdf Draft Oral Tablet 021290 03/01/2012
Bosentan https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bosentan Tablets for oral suspension NDA 209279 RC Feb 2019.pdf Draft Oral Tablet, For Suspension 209279 02/01/2019
Bosutinib Monohydrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203341.pdf Draft Oral Tablet 203341 09/01/2019
Bremelanotide Acetate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210557.pdf Draft Subcutaneous Solution 210557 03/24/2021
Brexanolone https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211371.pdf Draft Intravenous Solution 211371 06/01/2020
Brexpiprazole https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brexpiprizole_oral tablet_NDA 205422_RC05-17.pdf Draft Oral Tablet 205422 07/01/2017
Brigatinib https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brigatinib_draft_Oral tab_RLD 208772_RC09-18.pdf Draft Oral Tablet 208772 09/01/2018
Brilliant Blue G https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209569.pdf Draft Ophthalmic Solution 209569 12/17/2021
Brimonidine Tartrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate_topical gel_204708_RC09-15.pdf Draft Topical Gel 204708 09/01/2015
Brimonidine Tartrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine Tartrate_Ophthalmic Solution_NDA 021262_RV07-17.pdf Draft Ophthalmic Solution/Drops 0.15% 021262 07/01/2017
Brimonidine Tartrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate ophthalmic solution 0.025 NDA 208144 PSG Page RC May 2019.pdf Draft Ophthalmic Solution/Drops 208144 05/01/2019
Brimonidine Tartrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate_ophthalmic solution_NDA 021770_RV08-17.pdf Draft Ophthalmic Solution/Drops 0.1% 021770 10/01/2017
Brimonidine Tartrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate_ophthalmic solution_NDA 020613_RV08-17.pdf Draft Ophthalmic Solution/Drops 0.2% 020613 10/01/2017
Brimonidine Tartrate; Brinzolamide https://www.accessdata.fda.gov/drugsatfda_docs/psg/BRIMONIDINE TARTRATE BRINZOLAMIDE ophthalmic suspension drops NDA 204251 PSG Page RV May 2019.pdf Draft Ophthalmic Suspension/Drops 204251 05/01/2019
Brimonidine Tartrate;Timolol Maleate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brimonidine tartrate Timolol MaleateNDA 021398 RC 09-2018.pdf Draft Ophthalmic Solution/Drops 021398 09/01/2018
Brinzolamide https://www.accessdata.fda.gov/drugsatfda_docs/psg/BRINZOLAMIDE ophthalmic suspension drops NDA 020816 PSG Page RV May 2019.pdf Draft Ophthalmic Suspension/Drops 1% 020816 05/01/2019
Brivaracetam https://www.accessdata.fda.gov/drugsatfda_docs/psg/Brivaracetam_oral tablet_NDA 205836_RC05-17.pdf Draft Oral Tablet 205836 07/01/2017
Bromfenac Sodium https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromfenac sodium_ophthalmic solution_NDA 021664_RV08-17.pdf Draft Ophthalmic Solution/Drops 021664 10/01/2017
Bromocriptine Mesylate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromocriptine_ Mesylate_tab_17962_RC11-09.pdf Draft Oral Tablet 017962 11/01/2009
Bromocriptine mesylate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromocriptine Mesylate Tablets NDA20866 RC Feb 2019.pdf Draft Oral Tablet 020866 02/01/2019
Bromocriptine Mesylate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bromocriptine_ Mesylate_cap_17962_RC11-09.pdf Draft Oral Capsule 017962 11/01/2009
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205613.pdf Draft Rectal Aerosol, Foam 205613 11/18/2020
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021324.pdf Draft Oral Capsule, Delayed Release 021324 08/20/2021
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215935.pdf Draft Oral Capsule, Delayed Release 215935 11/17/2022
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211929.pdf Draft Oral Capsule, Extended Release 211929 03/01/2020
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020746.pdf Draft Nasal Spray, Metered 020746 08/01/2020
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide_Inhalation_Sus_20929_RC_09-12.pdf Draft Inhalation Suspension 020929 09/01/2012
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide_inhalation powder_RLD 21949_RC12-16.pdf Draft Inhalation Powder 021949 12/01/2016
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide_ERTab_203634_RC12-14.pdf Draft Oral Tablet, Extended Release 203634 12/01/2014
Budesonide; Formoterol Fumarate Dihydrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide and Formoterol fumarate dihydrate_MDI_021929_RC06-15.pdf Draft Inhalation Aerosol, Metered 021929 06/01/2015
Bumetanide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bumetanide_tab_74700_RV11-13.pdf Draft Oral Tablet 018225 11/01/2013
Bupivacaine https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupivacaine_ liposomal injectable injection_NDA 022496_RC11-17.pdf Draft Injection Injectable, Liposomal 022496 02/01/2018
Bupivacaine https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_204803.pdf Draft Infiltration Solution, Extended Release 204803 05/19/2022
Buprenorphine https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209819.pdf Draft Subcutaneous Solution, Extended Release 209819 06/01/2020
Buprenorphine https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021306.pdf Draft Transdermal Film, Extended Release 021306 06/01/2020
Buprenorphine Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine hydrochloride_buccal film_NDA 207932_RC11-17.pdf Draft Buccal Film 207932 02/01/2018
Buprenorphine Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine_hydrochloride_SLtab_78633_RV02-14.pdf Draft Sublingual Tablet 020732 02/01/2014
Buprenorphine Hydrochloride; Naloxone Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine_HCl;_Naloxone_HCl_subtab_20733_RC5-10.pdf Draft Sublingual Tablet 020733 05/01/2010
Buprenorphine Hydrochloride; Naloxone Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine Hcl; Naloxone Hcl_sublingual tablet_RLD 204242_RV12-16.pdf Draft Sublingual Tablet 204242 12/01/2016
Buprenorphine Hydrochloride; Naloxone Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine HCL_Naloxone HCL_Buccal Film_205637_RC03-15.pdf Draft Buccal Film 205637 03/01/2015
Buprenorphine Hydrochloride; Naloxone Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buprenorphine HCL; Naloxone HCL_sublingual buccal film_RLD 022410_RV12-16.pdf Draft Buccal, Sublingual Film 022410 12/01/2016
Bupropion Hydrobromide https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HBr_ERtab_22108_RV03-13.pdf Draft Oral Tablet, Extended Release 022108 03/01/2013
Bupropion Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HCl_ERtab_22497_RC03-13.pdf Draft Oral Tablet, Extended Release 022497 03/01/2013
Bupropion Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HCl_ERtab_21515_RV03-13.pdf Draft Oral Tablet, Extended Release 021515 03/01/2013
Bupropion Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HCl_ERtab_20358_20711_RV03-13.pdf Draft Oral Tablet, Extended Release 020358 020711 03/01/2013
Bupropion Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Bupropion_HCl_tab_18644_RV03-13.pdf Draft Oral Tablet 018644 03/01/2013
Bupropion Hydrochloride; Naltrexone Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200063.pdf Draft Oral Tablet, Extended Release 200063 11/18/2020
Buspirone Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/Buspirone_tab_18731_RC12-09.pdf Draft Oral Tablet 018731 12/01/2009
Busulfan https://www.accessdata.fda.gov/drugsatfda_docs/psg/Busulfan_tab_09386_RC7-08.pdf Draft Oral Tablet 009386 07/01/2009
Butenafine Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020524.pdf Draft Topical Cream 020524 10/21/2022
Butenafine Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021307.pdf Draft Topical Cream 021307 10/21/2022
Butoconazole Nitrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Butoconazole Nitrate Vaginal Cream ANDA 200923 RV Feb 2019.pdf Draft Vaginal Cream 200923 02/01/2019
Butoconazole Nitrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/Butoconazole Nitrate Vaginal Cream NDA 020421 RV Feb 2019.pdf Draft Vaginal Cream 020421 02/01/2019

Newly Added Guidances since November 17, 2022

Active Ingredient (link to Specific Guidance) URL Type Route Dosage Form RLD or RS Number Date Recommended
Ammonium Lactate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020508.pdf Draft Topical Cream 020508 11/17/2022
Ammonium Lactate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019155.pdf Draft Topical Lotion 019155 11/17/2022
Budesonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215935.pdf Draft Oral Capsule, Delayed Release 215935 11/17/2022
Calcitonin Salmon https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017769.pdf Draft Injection Injectable 017808 11/17/2022
Clindamycin Phosphate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215650.pdf Draft Vaginal Gel 215650 11/17/2022
Deferiprone https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212269.pdf Draft Oral Tablet 212269 11/17/2022
Drospirenone; Estetrol https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214154.pdf Draft Oral Tablet 214154 11/17/2022
Eteplirsen https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206488.pdf Draft Intravenous Solution 206488 11/17/2022
Fidaxomicin https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213138.pdf Draft Oral For Suspension 213138 11/17/2022
Fosdenopterin Hydrobromide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214018.pdf Draft Intravenous Powder 214018 11/17/2022
Hydrocortisone https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016199.pdf Draft Rectal Enema 016199 11/17/2022
Hydroxyurea https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208843.pdf Draft Oral Tablet 208843 11/17/2022
Inotersen Sodium https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211172.pdf Draft Subcutaneous Solution 211172 11/17/2022
Ketotifen Fumarate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021066.pdf Draft Ophthalmic Solution/Drops 021066 021996 11/17/2022
Magnesium Sulfate; Potassium Chloride; Sodium Sulfate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213135.pdf Draft Oral Tablet 213135 11/17/2022
Melphalan Flufenamide Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214383.pdf Draft Intravenous Powder 214383 11/17/2022
Miconazole Nitrate; White Petrolatum; Zinc Oxide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021026.pdf Draft Topical Ointment 021026 11/17/2022
Mometasone Furoate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215712.pdf Draft Nasal Spray, Metered 215712 11/17/2022
Nicardipine Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019488.pdf Draft Oral Capsule 019488 11/17/2022
Omeprazole Magnesium https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_078878.pdf Draft Oral Capsule, Delayed Release 078878 11/17/2022
Patisiran Sodium https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210922.pdf Draft Intravenous Solution 210922 11/17/2022
Ponesimod https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213498.pdf Draft Oral Tablet 213498 11/17/2022
Ranolazine https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216018.pdf Draft Oral Granules, Extended Release 216018 11/17/2022
Tepotinib Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214096.pdf Draft Oral Tablet 214096 11/17/2022
Tivozanib Hydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212904.pdf Draft Oral Capsule 212904 11/17/2022
Triamcinolone Acetonide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208845.pdf Draft Intra-Articular For Suspension, Extended Release 208845 11/17/2022
Trilaciclib Dihydrochloride https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214200.pdf Draft Intravenous Powder 214200 11/17/2022
Varenicline Tartrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213978.pdf Draft Nasal Spray 213978 11/17/2022
Voclosporin https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213716.pdf Draft Oral Capsule 213716 11/17/2022

Newly Revised Guidances since November 17, 2022

Active Ingredient (link to Specific Guidance) URL Type Route Dosage Form RLD or RS Number Date Recommended
Acyclovir https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203791.pdf Draft Buccal Tablet 203791 11/17/2022
Baricitinib https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207924.pdf Draft Oral Tablet 207924 11/17/2022
Calcium Carbonate; Famotidine; Magnesium Hydroxide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020958.pdf Draft Oral Tablet, Chewable 020958 11/17/2022
Daunorubicin Citrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050704.pdf Draft Injection Injectable, Liposomal 050704 11/17/2022
Deferiprone https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021825.pdf Draft Oral Tablet 021825 11/17/2022
Ethinyl Estradiol; Norethindrone Acetate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021065.pdf Draft Oral Tablet 021065 11/17/2022
Ferric Oxyhydroxide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020955.pdf Draft Injection Injectable 020955 11/17/2022
Ferric Oxyhydroxide https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017441.pdf Draft Injection Injectable 017441 11/17/2022
Goserelin Acetate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020578.pdf Draft Implantation Implant 020578 11/17/2022
Goserelin Acetate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_019726.pdf Draft Implantation Implant 019726 11/17/2022
Icosapent Ethyl https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202057.pdf Draft Oral Capsule 202057 11/17/2022
Lapatinib Ditosylate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022059.pdf Draft Oral Tablet 022059 11/17/2022
Lidocaine https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207962.pdf Draft Topical Patch 207962 11/17/2022
Oxycodone https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208090.pdf Draft Oral Capsule, Extended Release 208090 11/17/2022
Progesterone https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020701.pdf Draft Vaginal Gel 020701 11/17/2022
Ranolazine https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021526.pdf Draft Oral Tablet, Extended Release 021526 11/17/2022
Rifaximin https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021361.pdf Draft Oral Tablet 021361 11/17/2022
Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021892.pdf Draft Oral Tablet 021892 11/17/2022
Sumatriptan Succinate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020080-Vial.pdf Draft Subcutaneous Injectable, Vial 020080 11/17/2022
Sumatriptan Succinate https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020080-Autoinj.pdf Draft Subcutaneous Injectable, Autoinjector 020080 11/17/2022
Back to Top